CIAM
NKTR icon

Caitong International Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Caitong International Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$129K Buy
+1,798
New +$102K 0.02% 508
2025
Q4 		– Sell
-11
Closed -$626 – 2243
2025
Q3 		$626 Buy
+11
New +$364 ﹤0.01% 1530

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Caitong International Asset Management's NKTR Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 1,798 shares worth $129K. The stake represents 0.02% of the portfolio and ranks #508 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in NKTR as recently as Q3 2025.

Caitong International Asset Management first reported a position in NKTR in Q3 2025 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Caitong International Asset Management held 1,798 shares of Nektar Therapeutics worth $129K as of Q1 2026.
  • Nektar Therapeutics was a new Caitong International Asset Management position in Q1 2026.
  • Nektar Therapeutics made up 0.02% of Caitong International Asset Management's portfolio in Q1 2026, its #508 holding.
  • Caitong International Asset Management first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.